Pfizer Stock News

Pfizer-BioNTech is pressing for further expansion of its booster shots market to include teenagers, according to new reports by the Washington Post []

KARACHI: Minister for Health and Population Welfare, Sindh, Dr Azra Fazal Pechuho, held a Press Conference at the Sindh Assembly regarding the new Covid-19 variant, Omicron. The Minister stated that in order to combat this new variant the Federal Government will have to take precautions immediately. She also said that rapid antigen tests must be carried out at the airport and all other points of entry into the country. The Sindh government is ready to administer booster shots for the people free of cost, however, to do this the province needs at least 2 million doses of the Covid-19 vaccine. Dr Azra said that those people who get infected with Covid-19 despite having received the vaccine will have their genomic profiling done in order to pin down which variant is present in our population and its probability. Giving clarity on the new variant, the Minister also said that the virus has mutated so as to show difference in 30 locations of its anatomy. This means that there could be a difference in its rate of infection and how it affects the human body in comparison to the previous variants.

Pfizer Inc. will apply for authorization for its booster COVID-19 vaccine for ages 16 and 17 in the United States, US media reported. Health officials in the US currently recommend that all people ove

Pfizer is expected to seek authorization from the US Food and Drug Administration for its vaccine booster shot for those who are ages 16 and 17, a source familiar with the plan told CNN on Monday.

The finding comes as Pfizer seeks FDA emergency use approval for Paxlovid, which is a five-day antiviral pill regimen.

The outlook for the treatment, once bright, dims as Pfizer''s rival Covid-19 antiviral has had more positive data.

Viking Fund Management LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 6.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 158,000 shares of the biopharmaceutical companys stock after buying an additional 10,000 shares during the quarter. Pfizer []

Pfizer is among the Big Pharma companies trying to block legislation strengthening whistleblowers'' ability to report corporate fraud. The post Pfizer Is Lobbying to Thwart Whistleblowers From Exposing Corporate Fraud appeared first on The Intercept .

Pfizer (NYSE:PFE) had its price target upped by equities researchers at Morgan Stanley from $50.00 to $60.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has an equal weight rating on the biopharmaceutical companys stock. Morgan Stanleys price objective indicates a potential upside of 11.11% from the companys previous close. []

Counting Pharmaceutical Giant Pfizer as Anchor Tenant, Tishmans Spiral Development Is 54% Leased

Shares of Pfizer Inc . (NYSE: PFE ) traded today at $55.70, eclipsing its 12-month high. Approximately 40.2 million shares have changed hands today, as compared to an average 30-day volume of 35.7 million shares. Pfizer Inc. is currently priced 50.7% above its average consensus analyst price target of $26.50. Pfizer is one of the worlds largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its Full story available on Benzinga.com

Pfizer has already started working on a version of its Covid-19 vaccine specifically targeting the Omicron variant in case the current inoculation is not effective against the new strain, the US drugmaker''s CEO Albert Bourla said Monday.

BioNTech and Pfizer are both currently conducting studies to test whether their current shot may be effective against Omicron.